Bionaut and AnalytiCon Enter Into a Lead Optimization Collaboration

Bionaut Pharmaceuticals and AnalytiCon Discovery GmbH announced today a service and collaboration agreement to identify novel anti-cancer compounds that inhibit the ability of tumor cells to survive stress conditions. Bionaut will provide to the collaboration a series of compounds that have shown potent in vivo activity in various human tumor xenograft models and use its Sentinel Pathway Reporter System to validate new compounds. AnalytiCon will apply its natural product and medicinal chemistry expertise to optimize the activity and selectivity of these compounds for further pre-clinical development by Bionaut. Financial terms were not disclosed.

Big News Network (http://feeds.bignewsnetwork.com/redir.php?jid=219c35ca8e6aa814&cat=6dcd932030878143)